New York, May 29, 2026, 04:13 (EDT)
- PPBT last traded at $2.81 in the U.S., off 16 cents from its previous close.
- The company’s recent $200 million shelf registration leaves financing and dilution risk on the table.
- Biotech indexes gained, but Purple Biotech trailed its sector’s move.
Purple Biotech Ltd’s American Depositary Shares last traded at $2.81 in the U.S., off 16 cents from the previous close. The Israeli cancer drug developer faces investor questions over its cash position and early pipeline updates.
Purple’s funding position takes the spotlight now, not just its pipeline. The company is still in the development phase, and its main CAPTN-3 program is preclinical. That means there hasn’t been any patient-outcome data from human efficacy trials yet.
The stock trailed the broader biotech move. The SPDR S&P Biotech ETF rose around 1.1% and the iShares Nasdaq Biotechnology ETF added about 1.4% in recent trading. Oncology-antibody stocks showed mixed action, with Janux Therapeutics gaining roughly 2.1% and MacroGenics falling about 3.8%.
Purple filed a Form F-3 shelf registration with the SEC on May 20 for up to $200 million in securities. This lets the company register securities for sale as needed, not all at once. The filing said any offering would need a prospectus supplement. Because Purple’s public float is still under $75 million, primary offerings are limited to about $824,331 in any 12-month window under this filing.
Purple Biotech said it had $6.4 million in cash, cash equivalents and short-term deposits at the end of March, and management expects that to last through 2027. The company had a net loss of $0.1 million for the first quarter. Adjusted net loss increased to $2.1 million, up from $1.3 million a year ago.
Purple CEO Gil Efron called the CAPTN-3 platform the company’s main value driver. “We continue to advance the CAPTN-3 platform as a core value driver,” he said in the company’s May 15 results statement. The platform uses a tri-specific antibody, a lab-made protein that targets three things at the same time.
Purple said lab tests on patient-derived tumor samples back IM1240. The company’s capped-CD3 × 5T4 × NKG2A tri-specific antibody worked on samples that had resisted treatment. That’s supportive evidence in the lab, though it is not clinical proof from patients who got the drug.
Janux says it’s working on tumor-activated T-cell engagers, which is another immuno-oncology method aimed at directing immune cells at tumors. MacroGenics calls itself a clinical-stage developer focused on next-gen antibody-based cancer drugs.
Bulls are staring down real risks. Preclinical tumor results might not help people, and small biotechs like Purple often run low on cash before late-stage studies. In its SEC filing, Purple warns about fast-moving rivals in cancer, intellectual-property troubles, risks from its work in Israel, and says it could miss Nasdaq’s listing rules.
Right now, the stock trades more like a financing story than a pure play on cancer tech. New CAPTN-3 data, a less dilutive raise, or a deal might shift that, but so far that hasn’t happened. For now, PPBT faces thin trading, cash worries, and the biotech risk—early data still needs to get through trials.
